T22-GFP-H6 nanoparticles could effectively target and selectively internalize in several CXCR4+ tumor cells, such as colorectal cancer, diffuse large B cell lymphoma and head and neck squamous cell carcinoma tumor. Here, CXCR4 is linked to neoplasm.